CATALOGO DEI PRODOTTI DELLA RICERCA

CORBO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.207
NA - Nord America 2.918
AS - Asia 1.270
OC - Oceania 16
SA - Sud America 6
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.899
GB - Regno Unito 1.147
CN - Cina 980
IT - Italia 617
IE - Irlanda 284
SE - Svezia 271
FR - Francia 244
RU - Federazione Russa 207
DE - Germania 184
SG - Singapore 124
FI - Finlandia 112
VN - Vietnam 51
UA - Ucraina 47
HK - Hong Kong 35
BE - Belgio 24
AT - Austria 16
IR - Iran 14
AU - Australia 13
CZ - Repubblica Ceca 13
IN - India 13
KR - Corea 13
NL - Olanda 13
CA - Canada 12
JP - Giappone 12
TR - Turchia 7
CH - Svizzera 4
ES - Italia 4
KG - Kirghizistan 4
AL - Albania 3
CR - Costa Rica 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BR - Brasile 2
CL - Cile 2
ID - Indonesia 2
IL - Israele 2
LK - Sri Lanka 2
MA - Marocco 2
MX - Messico 2
NO - Norvegia 2
PA - Panama 2
PL - Polonia 2
RO - Romania 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
DK - Danimarca 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GR - Grecia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 7.422
Salva come PNG Salva come JPEG
Città #
Southend 1.100
Chandler 706
Verona 297
Dublin 269
Beijing 235
Jacksonville 234
Ann Arbor 220
Woodbridge 206
Ashburn 140
New York 111
Jinan 104
Lawrence 97
Princeton 97
Wilmington 90
Redmond 83
Houston 72
Singapore 72
Shenyang 67
Nanjing 64
Hebei 49
Sindelfingen 41
Helsinki 40
Zhengzhou 38
Haikou 37
Tianjin 34
Dearborn 33
Ningbo 33
Changsha 32
Hong Kong 30
Dong Ket 28
Hangzhou 27
Brussels 24
Seattle 24
Bologna 23
Taiyuan 23
Redwood City 22
Milan 21
Taizhou 19
Guangzhou 18
Jiaxing 17
Nanchang 17
Vienna 16
Boardman 15
Norwalk 15
Washington 15
Kent 14
Los Angeles 14
San Francisco 13
Cagliari 12
Seoul 12
Lanzhou 11
Brno 10
Fuzhou 10
Tokyo 10
Chicago 9
Dongguan 9
Falls Church 9
Rome 9
Chions 8
Lancaster 8
Munich 8
Fairfield 7
Lappeenranta 7
Sydney 7
Toronto 6
Ardabil 5
Augusta 5
Kochi 5
Sundbyberg 5
Amsterdam 4
Auburn Hills 4
Bishkek 4
Menlo Park 4
Montereale Valcellina 4
Moscow 4
Mumbai 4
Nova Milanese 4
San Diego 4
Tombolo 4
Trevenzuolo 4
Auckland 3
Cambridge 3
Central 3
Chengdu 3
Clearwater 3
Fano 3
Kemerovo 3
Leawood 3
Melbourne 3
Riga 3
Riva 3
San Giovanni Lupatoto 3
San José 3
San Pietro in Cariano 3
Santorso 3
Spring 3
Tirana 3
Torino 3
Trento 3
Zanjan 3
Totale 5.272
Salva come PNG Salva come JPEG
Nome #
Whole-genome landscape of pancreatic neuroendocrine tumours 161
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 153
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. 139
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 131
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 126
Genomic analyses identify molecular subtypes of pancreatic cancer 125
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 120
Reporting tumor molecular heterogeneity in histopathological diagnosis 120
RON is not a prognostic marker for resectable pancreatic cancer 117
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 113
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 107
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 104
PD-1, PD-L1 and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications 103
Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation 102
Mutational analysis of cancer candidate genes in different pancreatic cancer types 101
Lost in translation: returning germline genetic results in genome-scale cancer research 100
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 99
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 97
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 96
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases 95
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 93
Profiling mTOR pathway in neuroendocrine tumors. 92
Molecular biology of neuroendocrine tumors 89
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 87
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. 86
Pancreatic cancer genomics 86
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 86
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 85
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 85
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries 84
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. 84
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 83
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 83
Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma 82
Mutational profile of GNAQQ209 in human tumors 82
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 82
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 81
Fhit down-regulation is an early event in pancreatic carcinogenesis 81
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 81
Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas 80
Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells 79
Hypermutation In Pancreatic Cancer 78
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer 78
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer 78
Whole genomes redefine the mutational landscape of pancreatic cancer 77
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling 75
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 75
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 74
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 73
Complete neural stem cell (nsc) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism 72
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 72
Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data 72
Profiling mTOR pathway in neuroendocrine tumors 71
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 70
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 69
Exosomal miRNA signatures of pancreatic lesions 69
Molecular alterations in basal cell carcinoma subtypes 68
Comparative Lesions Analysis Through a Targeted Sequencing Approach 66
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer 65
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation 63
MEN1 Gene Mutation and Reduced Expression Are Associated with Poor Prognosis in Pulmonary Carcinoids 60
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 60
Organoid models of human and mouse ductal pancreatic cancer. 60
Muscle derangement and alteration of the nutritional machinery in NSCLC 60
Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study 60
Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization 59
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 58
The RAS and YAP1 dance, who is leading? 56
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer 56
Combinatorial Effect of Magnetic Field and Radiotherapy in Pancreatic Ductal Adenocarcinoma Organoids 55
Sex differences in oncogenic mutational processes 54
Preclinical Modelling of PDA: Is Organoid the New Black? 53
Generation of Pancreatic Organoid-Derived Isografts 52
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients 52
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 51
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 50
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 50
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 47
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 46
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance 46
Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines 45
Current role of non-coding RNAs in the clinical setting 45
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer 45
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis 44
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 44
Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple 42
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan 42
Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium 40
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer 39
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer 38
p53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer 38
Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk 37
Loss of FGFR4 promotes the malignant phenotype of PDAC 36
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification 36
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size 36
Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic 36
Lamc2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth 34
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer 33
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 33
Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care 30
Totale 7.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.974
article - articoli 25.057
book - libri 0
conference - conferenze 1.121
curatela - curatele 0
other - altro 1.076
patent - brevetti 0
selected - selezionate 0
volume - volumi 720
Totale 55.948
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020779 0 33 49 30 80 73 117 76 41 75 101 104
2020/2021870 116 122 45 135 107 84 23 23 28 25 79 83
2021/2022979 95 311 33 50 39 37 29 58 35 16 76 200
2022/20231.889 113 222 150 328 160 453 23 115 230 19 41 35
2023/20241.225 43 76 78 106 139 211 61 144 29 85 186 67
2024/2025255 179 76 0 0 0 0 0 0 0 0 0 0
Totale 7.684